The patent entitled: ‘Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors,’ protects NX002 and related compounds.
Currently, NX002 is in preclinical development for the treatment of mucositis and has showed efficacy in a study evaluated well-validated animal models of oral mucositis.
NephRx president and CEO James Koziarz said issuance of this most recent patent further confirms the promising utility of NX002 as a potential treatment for oral mucositis.
"We look forward to advancing the detailed NX002 toxicity studies needed to initiate the mucositis clinical program for NX002," Koziarz said.